Highlighting the need for worldwide collaboration on cerebral microbleeds: the Microbleeds International Collaborative Network

*Microbleeds International Collaborative Network*
We were interested and encouraged to read the recent letter calling for international collaborations on the topic of cerebral microbleeds (CMBs) (http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(16)30124-7/fulltext). Key questions remain about the clinical relevance of CMBs, particularly regarding their potential role as a marker of bleeding-prone arteriopathies and intracerebral haemorrhage risk in patients treated with antithrombotic agents following ischaemic stroke or TIA.1,2 We agree that single-centre studies are unlikely to fully answer all of the important scientific questions about CMBs; international collaboration is essential to increase the scale of data available, maximizing scientific and statistical power. Collaborative research networks relating to CMBs have developed over recent years.3 We wish to raise awareness of the recently established Microbleeds International Collaborative Network, which arose from two large multicentre inception cohort studies addressing the key question of whether CMBs are associated with increased bleeding risk on oral anticoagulants in patients following ischaemic stroke or TIA: Clinical Relevance of Microbleeds in Stroke (CROMIS-2:https://www.ucl.ac.uk/cromis-2, and https://clinicaltrials.gov/ct2/show/NCT02513316) and Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance (HERO; http://heropub.pic.es; https://clinicaltrials.gov/ct2/show/NCT02238470). Together, CROMIS-2 and HERO have successfully recruited over 2500 patients from over 110 hospitals in the UK and Spain, and will report their first results in 2017. The teams leading these observational studies, together with investigators leading other relevant study groups and cohort studies worldwide, have established a Microbleeds International Collaborative Network. We aim to undertake high quality large-scale robust pooled analyses relating to CMBs that are free from biases, including selective inclusion and outcome reporting. With these aims in mind, our first project is a systematic review and individual patient data meta-analysis of the clinical relevance of CMBs in patients with TIA and ischaemic stroke (the prospectively registered protocol is published at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016036602). This project is conducted according to the PRISMA-IPD standards for reporting systematic reviews and individual patient data meta-analyses. We held a successful investigator workshop at the European Stroke Organisation Conference in Barcelona, May 2016, with input from 16 groups from 14 countries worldwide, who worked to finalize the protocol and set timelines. Following this workshop, our team has access to data from over 10000 individuals (Table); we warmly welcome other investigators to contribute to expanding this research effort.
Important work is also needed to standardize acquisition sequences, lesion definition and measurement, and post-processing of neuroimaging markers of small vessel disease. Members of the Microbleeds International Collaborative Network thus work closely with large-scale international harmonization initiatives including STRIVE\textsuperscript{4} and COEN.\textsuperscript{5}

Large-scale collaborative systematic reviews and pooled analyses will provide the strongest evidence to incorporate CMB imaging into clinical practice, including precise estimates of the ischaemic stroke and intracerebral haemorrhage risks associated with antithrombotic (antiplatelet and anticoagulant) drug exposure in patients with CMBs. The Microbleeds International Collaborative Network endorses the need for global collaboration on CMBs and small vessel disease research more widely; full, open communication and collaboration are essential to avoid unplanned duplication of effort. We look forward to working with other researchers worldwide to tackle the many outstanding research questions relating to CMBs.

**Funding**

The Stroke Association and British Heart Foundation fund the CROMIS-2 study including providing support for the Microbleed International Collaborative Network. The NOACISP registry is supported by a grant from the Swiss Heart Foundation. The HERO study received funding from Fondo de Investigaciones Sanitarias (PI11/00296), RETICS INVICTUS (RD012/0014/0002 and FEDER (Fondo Europeo de Desarrollo Regional). SAMURAI-NVAF was supported in part by a Grant-in-Aid (H23-Junkanki-Ippan-010) from the Ministry of Health, Labour and Welfare, Japan. The HAGAKURE study was supported by a Grant-in-Aid for Scientific Research (C), JSPS KAKENHI (Grant Number 15k10364). The IPAAC study is partially funded by a Hong Kong HMRF (Health and Medical Research Grant). The MICRO study was supported by the Netherlands Heart Foundation (grant 2001B071).
References


Microbleed International Collaborative Network – list of participants
(in alphabetical order)

Ambler G1, Al-Shahi Salman R2, Ay H3, Engelter S4, Fazekas F5, Fluri F4,6, Gattringer T5, Gomez-Anson B7, Horstmann S8, Jäger HR1, Kelly P9, Kwa VIH10, Lip GYH11, Marti-Fabregas J7, Michel P12, Muellges W7, Orken DN13, Peters N4, Prats Sanchez L7, Sato S14, Seiffge D4, Shakeshaft C1, Soo Y15, Thijs V16, Veltkamp R17, Werring DJ1, Wilson D1, Wong LKS15, Yakushiji Y18

1Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
2University of Edinburgh, UK
3Massachusetts General Hospital, Harvard Medical School, Boston, USA
4Department of Neurology and Stroke Center, University Hospital Basel, Basel, Switzerland
5Department of Neurology, Medical University of Graz, Graz, Austria
6Department of Neurology, University Hospital Würzburg, Josef-Schneider Strasse 11, 97080 Würzburg, Germany
7Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute, IIB-Sant Pau, Barcelona, Spain
8University of Heidelberg, Germany
9Neurovascular Unit for Applied Translational and Therapeutics Research, Mater University Hospital/Dublin Academic Medical Centre, Dublin, Ireland
10Department of Neurology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
11University of Birmingham, Birmingham, UK
12Centre Cérébrovasculaire, Service de Neurologie, Département des Neurosciences Cliniques, CHUV, Lausanne
13Department of Neurology, Sisli Etfal Education and Research Hospital, Istanbul, Turkey
14Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
15Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
16Department of Neurology, Austin Health and Melbourne Brain Center, University of Melbourne, Victoria, Australia
17Department of Stroke Medicine, Division of Brain Sciences, Imperial College London, United Kingdom

18Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Saga, Japan